Home > Oncology > ASCO 2021 > Haematological Cancers > Acalabrutinib as effective but better tolerated than ibrutinib in CLL

Acalabrutinib as effective but better tolerated than ibrutinib in CLL

Presented By
Prof. John Byrd, Ohio State University Comprehensive Cancer Center, OH, USA
Conference
ASCO 2021
Trial
Phase 3, ELEVATE-RR
In the first head-to-head trial of BTK inhibitors in previously treated chronic lymphocytic leukaemia (CLL), acalabrutinib demonstrated non-inferior progression-free survival with less cardiotoxicity and fewer discontinuations due to adverse events compared with ibrutinib. Bruton tyrosine kinase (BTK) is critical for CLL tumour cell proliferation and survival [1]. Ibrutinib, the first BTK inhibitor approved for adults with CLL, is associated with adverse events, particularly cardiovascular toxicities, that can lead to treatment discontinuation [2]. The randomised, non-inferiority, phase 3 ELEVATE-RR trial (NCT02477696) compared ibrutinib and acalabrutinib, a second-generation BTK inhibitor, in previously treated patients with CLL requiring therapy. The study randomised 533 patients 1:1 to receive acalabrutinib (100 mg twice daily) or ibrutinib (420 m...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on